Literature DB >> 15321029

Efficacy of low concentrations of ketorolac tromethamine in animal models of ocular inflammation.

L David Waterbury1, Allan J Flach.   

Abstract

PURPOSE: To determine if topical ophthalmic application of ketorolac tromethamine concentrations below 0.5% can block the biochemical and physiological processes associated with chemically induced ocular inflammation in rabbits.
METHODS: Ocular inflammation was induced in rabbits by intravenous (i.v.) injection of endotoxin (2.5 microg/kg) isolated from Salmonella typhimurium, or by a topical application of arachidonic acid (1.0%). The effect of ketorolac (at concentrations ranging from 0.001%-0.5%) on ocular inflammation was determined by measuring changes in the blood-aqueous barrier, using fluorophotometry (dextran-isothiocyanate-fluorescein; FITC-dextran 2%) and by measuring changes in aqueous humor protein concentrations. Changes in aqueous humor prostaglandin E(2) (PGE(2)) concentrations were also measured.
RESULTS: Ketorolac 0.01%-0.5% produced substantial decreases in endotoxin-induced fluorescein leakage into the aqueous humor. The decrease produced by ketorolac 0.1% was comparable to that produced by ketorolac 0.5%. Ketorolac 0.1%-0.5% produced substantial decreases in endotoxin-induced increases in prostaglandin concentrations in the aqueous humor, and in arachidonic acid-induced protein leakage into the aqueous humor.
CONCLUSIONS: Topical application of ketorolac concentrations as low as 0.01%-0.1% significantly reduce chemically induced ocular inflammation in rabbits.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15321029     DOI: 10.1089/1080768041725380

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  2 in total

1.  Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.

Authors:  L David Waterbury; Danielle Galindo; Linda Villanueva; Cathy Nguyen; Milan Patel; Lisa Borbridge; Mayssa Attar; Rhett M Schiffman; David A Hollander
Journal:  J Ocul Pharmacol Ther       Date:  2011-02-25       Impact factor: 2.671

2.  Ocular pharmacokinetics of 0.45% ketorolac tromethamine.

Authors:  Mayssa Attar; Rhett Schiffman; Lisa Borbridge; Quinn Farnes; Devin Welty
Journal:  Clin Ophthalmol       Date:  2010-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.